What Worked For Sinovac To Enter WHO's EUL? Covaxin Yet To Open Its Doors!

In a recent development, the World Health Organisation gave it's approval to China's COVID vaccine Sinovac to be used under Public Health Emergency. But, sadly, Covaxin, which has been produced by India's manufacturing unit, Bharat Biotech, is still non-qualified to go, causing a hiccup for those who already have been fully vaccinated against COVID-19 and would not be able to travel internationally till it gets approved.


At present, Covaxin is approved in just nine nations all over the world- Iran, Philippines, Mauritius, Mexico, Paraguay, Zimbabwe, Nepal, Guyana and India whereas Covishield (the Indian AstraZeneca) has been accepted widely across 130 countries.

A week back, Bharat Biotech had already sent its proposal to WHO and after its findings, it was learnt that only 90 percent of the documentation was complete and rest was yet to be assured and shared by the company. Till date, over two crores of people have been vaccinated in India so far. After pulling down the restrictions and giving a full-fledged validation by the international health watchdog, WHO, Covaxin could be provided to the countries in need without any doubt.

Two of the terms by the WHO- 'EUA & EUL' formed the most important criteria for the inclusion of the vaccines under the list of emergency vaccines. 

As per WHO's diction-pedia, the straight definition of Emergency Use Authorisation (EUA) on it's website visually and technically appears as- 'A regulatory mechanism that gives validation for the use of vaccines and medicines to reduce the severity of life-threatening diseases that has been considered pandemic worldwide, whereas, Emergency Used Listing (EUL) can be defined as a risk-based procedure for the assessment and listing of the unlicensed vaccines, therapeutics and in-vitro diagnostics to help people affected by a Public Health Emergency worldwide.

EUA's precise assessment of laboratory and clinical trial data includes data-based quality, safety, production of protective antibodies and the efficiency of the vaccines or medicines is conducted to evaluate the risk-versus-benefit outcome with respect to the gravity of emergency across the world.

After a thorough examination and completion of all basic parameters, once the vaccine or the medicine meets out the standard emergency procedures, is provided a license for public health emergency use.

According to WHO listing criteria for EUL, four important focal points are meant to be met by the vaccine- a) The disease for which the product is intended is serious or immediate life-threatening or has the potential of causing an outbreak, epidemic, or pandemic and it is reasonable to consider the product for an EUL assessment; b) existing products have not been successful in eradicating the disease or preventing outbreaks; c) the product is manufactured in compliance with current Good Manufacturing Practices (GMP) and under a functional Quality Management System (QMS) in the case of in-vitro diagnostics; and d) the applicant undertakes to complete the development of the product (validation and verification) and apply for World Health Organisation pre-qualification once the product is licensed.

Moreover, there are other application requisites based on manufacturing quality data, labelling details, safety and efficiency of the vaccines that needs to be assessed thoroughly by the concerned department affiliated with the WHO.

China's Beijing-based pharmaceutical company's produce 'COVID vaccine-Sinovac' prevented symptomatic diseases up to 51 percent in those who were fully-vaccinated and foiled the severity of the COVID-19 virus and hospitalisation up to 100 percent in the subjects that were examined closely, as per the WHO's report. The Chinese vaccine met the international standards in criteria like safety, efficiency and manufacturing. 


Sinovac has largely done well in countries like Chile and Brazil and is an inactivated form of vaccine. Also, SAGE (Strategic Advisory Group of Experts on Immunisation), a principal advisory body to WHO gave it's full consent after finishing its review. 

Adults over the age of 18 and older are eligible to the vaccine. Because of the lack of sufficient clinical data for the people in the age group above 60, the real efficacy of the vaccine could not be estimated and hence, the WHO hasn't given its consent for that age group.

At present, only seven vaccines have earned their scores to be bracketed under EUL's inventory of public health emergency use- Pfizer/BioNTech; AstraZeneca-SKBio; Serum Institute of India (SII), AstraZenecaEU, Janssen; Moderna and Sinopharm.

India's Covaxin needs to earn it's vaccine efficacy proficiency in the eyes of the World Health Organisation in order to qualify all its fundamentals to be labeled as EUL.

By- Rashmi Singh

#COVID19 #Covaxin #Sinovac #Vaccination #COVIDPrevention #WHO #EUL #EUA #SAGE #PublicHealthEmergency

Technical terms | source- WHO

Comments

Post a Comment

Popular posts from this blog

WHO proposes framework for a safer, transparent & ethical use of human genome editing tools worldwide!

Image
The World Health Organisation released a two-new companion reports impending the first global recommendations to fortify human genome editing mechanism with safety, effectiveness and ethics for its proper use in public health practices. The forward-looking new reports result from the first broad, global consultation that spanned over two years, involving hundreds of participants representing diverse perspectives from around the world, including scientists and pioneering researchers, patient groups, faith leaders and indigenous peoples to draw a comprehensive and inclusive approach over the ethical and clean practices of human genome editing in the underlying areas of somatic, germline and heritable tissues. “Human genome editing has the potential to advance our ability to treat and cure disease, but the full impact will only be realized if we deploy it for the benefit of all people, instead of fuelling more health inequity between and within countries,” stated  Dr. Tedros Adhan
Read more

Way Forward- #PostCOVID (A brief introspection from my end)

Image
India needs coordinated efforts from people across different walks of life. Not only governments, political leaders, scientists and doctors, but also industrialists, economists, advisors, civil society members, educators and scholars from different fields to share their valuable introspection, knowledge and understanding regarding their experiences and proven practices to counter the after effects and post consequences inflicted by the COVID-19 disease in a more intense yet placid manner. The evolution and transmission of SARS-CoV-2 and its prevalent mutants is becoming a cause of concern for global leaders and institutions. The health care systems across the world have majorly collapsed due to the constant attack by the virus and its newly mutated forms. Delta and its variants have overpowered other variants for the past few days and it is reported to have spread across 11 countries including America. There were 40 cases reported across India too. Vaccination is just one of the given
Read more

COVID's new mutant spell 'Omicron' knocks the world with a silent hit

Image
Having first reported to the World Health Organisation from South Africa on 24 th of November 2021, the newly circulating mutant ‘ Omicron’ or ‘B.1.1.529 ’ is becoming a cause of public health concern to the entire world. The first case of infection was confirmed from a specimen collected in the second week of November. The WHO’s independent group of experts (the Technical Advisory Group on SARS-CoV-2 virus Evolution/TAG-VE) assessed the potential impact of SARS-CoV-2 variant ‘B.1.1.529’ during a convention organised on 26 th of November. According to TAG-VE, the variant has a large number of mutations, some of which are becoming the reason of concern. The number of cases are apparently increasing day-by-day in almost all province regions of South Africa. Just on Sunday, the number of cases reported were 2800, much higher than the cases reported on a daily basis. Researchers all across the world including South Africa are conducting studies on this variant to have a better underst
Read more